{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:11:58Z","timestamp":1794651118722,"version":"4.9.1"},"reference-count":137,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Coalition for Epidemic Preparedness & Innovation"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Vaccines"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/14760584.2024.2397006","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:53:58Z","timestamp":1724720038000},"page":"796-811","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":66,"title":["Vaccines against mpox: MVA-BN and LC16m8"],"prefix":"10.1080","volume":"23","author":[{"given":"John D.","family":"Grabenstein","sequence":"first","affiliation":[{"name":"Vaccine Dynamics","place":["Easton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Hacker","sequence":"additional","affiliation":[{"name":"Coalition for Epidemic Preparedness & Innovation","place":["Oslo, Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,9]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1005769107"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.04.062"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltad020"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28701"},{"key":"e_1_3_6_7_1","first-page":"29","article-title":"Epidemiology of human mpox\u2014worldwide, 2018\u20132021","volume":"98","author":"McCollum AM","year":"2023","unstructured":"McCollum AM, Shelus V, Hill A, et al. Epidemiology of human mpox\u2014worldwide, 2018\u20132021. Wkly Epidemiological Rec. 2023;98:29\u201336. Available from: https\/\/iris.who.int\/bitstream\/handle\/10665\/365629\/WER9803-eng-fre.pdf?","journal-title":"Wkly Epidemiological Rec"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2023.106156"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00055-5"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/17.3.643"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2022.198932"},{"key":"e_1_3_6_12_1","unstructured":"World Health Organization: Situation Report. Multi-country outbreak of mpox external situation report #32. 2024 Apr 30. Available from: https:\/\/www.who.int\/publications\/m\/item\/multi-country-outbreak-of-mpox\u2013external-situation-report-32\u201330-april-2024"},{"key":"e_1_3_6_13_1","unstructured":"Strategic Advisory Group of Experts on Immunization. Monkeypox vaccines technical documents 16 November 2022 [internet]. Geneva: WHO; 2022 [cited 2024 Apr 28]. Available from: www.who.int\/groups\/strategic-advisory-group-of-experts-on-immunization\/monkeypox-vaccines-technical-documents"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2220415120"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid3003.230861"},{"issue":"27","key":"e_1_3_6_16_1","first-page":"351","article-title":"Smallpox and mpox (orthopoxviruses): WHO Position Paper, August 2024","volume":"99","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Smallpox and mpox (orthopoxviruses): WHO Position Paper, August 2024. Wkly Epidemiological Rec. 2024;99(27):351\u2013362. Available from: https:\/\/www.who.int\/publications\/i\/item\/10665-378522","journal-title":"Wkly Epidemiological Rec"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0003171"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.32607\/20758251-2017-9-4-4-12"},{"key":"e_1_3_6_19_1","unstructured":"NCT05846243 double-blind comparative randomized placebo-controlled study on immunogenicity reactogenicity and safety of live cell-based vaccine against smallpox and other orthopoxvirus infections (VAC\u03946 vaccine) in volunteers aged 18-60 years. [cited 2024 Jun 18]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05846243"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1086\/421266"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02089-12"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1101\/2024.01.31.24302065"},{"key":"e_1_3_6_23_1","unstructured":"Food & drug administration Jynneos product information and supporting documents 2019 [internet]. Silver Spring (MD): FDA; 2019 [cited 2024 Apr 28]. Available from: www.fda.gov\/vaccines-blood-biologics\/Jynneo.s Includes FDA\u2019s summary basis of approval and clinical review memo."},{"key":"e_1_3_6_24_1","unstructured":"European Public Assessment Report (EPAR). Imvanex (smallpox and monkeypox vaccine (live modified vaccinia virus Ankara)) overview May 22 2024[Internet]. Amsterdam: EMA; 2024 [cited 2024 Jun 16]. Available from: www.ema.europa.eu\/en\/documents\/variation-report\/imvanex-h-c-002596-ii-0076-epar-assessment-report-variation_en.pdf"},{"key":"#cr-split#-e_1_3_6_25_1.1","unstructured":"Japan Pharmaceuticals & Medical Devices Agency (PMDA). Pharmaceutical affairs and food sanitation council. Report on the deliberation results smallpox vaccine prepared in cell culture LC16 \"KMB \" 2022 August 1 (English) [internet]. Tokyo: PMDA"},{"key":"#cr-split#-e_1_3_6_25_1.2","unstructured":"2022 [cited 2024 Apr 28]. Available from: www.pmda.go.jp\/files\/000247943.pdf"},{"key":"e_1_3_6_26_1","unstructured":"Health Canada regulatory decision summary for imvamune November 5. 2020 [internet]. Ottawa: Health Canada; 2020 [cited 2024 Apr 28]. Available from: https:\/\/www.dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/RDS00720"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.571"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.8.1.13"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.03.020"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.aivir.2016.07.001"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.111"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.03.087"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1261"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir527"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300290"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/v14112496"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00574-6"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2023.2289270"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq162"},{"issue":"1","key":"e_1_3_6_40_1","first-page":"124","article-title":"MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults","volume":"12","author":"Nicol MP","year":"2010","unstructured":"Nicol MP, Grobler LA. MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults. Curr Opin Mol Ther. 2010;12(1):124\u2013134.","journal-title":"Curr Opin Mol Ther"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.08.050"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.06.006"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1108143"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0147-9571(03)00025-0"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.22.10847"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.03.016"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature02331"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.12.7845-7851.2005"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804985105"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03481-12"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2005.06.043"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.010553-0"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00056-12"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit105"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis753"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817307"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00270-0"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41587-x"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac455"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.10.078"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab111"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102420"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02090-w"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.06.075"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2215846"},{"key":"e_1_3_6_66_1","unstructured":"Food & drug administration. Mpox emergency use authorization information updated March 4 2024 [internet]. Silver Spring (MD): FDA; 2024 [cited 2024 Apr 28]. Available from: www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization#monkeypox"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2023-056055"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48180-w"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.06.021"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1101\/2024.04.25.24306078"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.18320"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7149a5"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00057-9"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad584"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7220a3"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215201"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad528"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7220a4"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02229-3"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad645"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1101\/2023.10.04.23296566v1"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2024.29.21.2300608"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.26.24303362v1"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.50.2200882"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2211944"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.12.066"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2023.28.24.2200883"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7320a3"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7236a4"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7233a3"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.48.2200894"},{"key":"e_1_3_6_92_1","unstructured":"Mvabea Ebola vaccine (MVA-BN-Filo [Recombinant]) Bavarian Nordic updated August 18 2023. European Public assessment report EMA [internet]. Amsterdam: EMA; 2023 [cited 2024 Apr 28]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mvabea"},{"key":"e_1_3_6_93_1","unstructured":"Bavarian Nordic prescribing information: jynneos (smallpox and monkeypox vaccine live non-replicating) United States September 29 2023 [internet]. Silver Spring (MD): FDA; 2023 Sep 29 [cited 2024 Apr 28]. Available from: www.fda.gov\/vaccines-blood-biologics\/Jynneos"},{"key":"e_1_3_6_94_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7149a4"},{"key":"e_1_3_6_95_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.7683"},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15830"},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.12.068"},{"key":"e_1_3_6_98_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054407"},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.04.052"},{"key":"e_1_3_6_100_1","unstructured":"Centers for Disease Control & Prevention. US recommended adult immunization schedule adult immunization schedule by age (addendum updated February 29 2024) recommendations for ages 19 years or older United States 2024 [internet]. Atlanta: CDC; 2024 [cited 2024 Apr 28]. Available from: www.cdc.gov\/vaccines\/schedules\/hcp\/imz\/adult.html"},{"key":"e_1_3_6_101_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200072"},{"key":"e_1_3_6_102_1","unstructured":"Canada\u2019s national advisory committee on immunization (NACI) rapid response: interim guidance on the use of imvamune in the context of monkeypox outbreaks in Canada. November 22 2022. Ottawa: NACI; 2022 [cited 2024 Apr 28]. Available from: www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/guidance-imvamune-monkeypox.html"},{"key":"#cr-split#-e_1_3_6_103_1.1","unstructured":"Joint committee on vaccination & immunisation (JCVI): immunisation against infectious disease (the \"Green Book\"): w ww.Gov.uk\/government\/collections\/immunisation-against-infectious-disease-the-green-book. Chapter 29: smallpox and monkeypox 2022 September 26 [internet]. London: JCVI"},{"key":"#cr-split#-e_1_3_6_103_1.2","unstructured":"2022 [cited 2024 Apr 28]. Available from: assets.publishing.service.gov.uk\/media\/63318341d3bf7f567fd9eb87\/Green-Book-chapter-29_Smallpox-and-monkeypox_26September2022.pdf"},{"key":"e_1_3_6_104_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7122e1"},{"key":"e_1_3_6_105_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofv040"},{"key":"e_1_3_6_106_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138348"},{"key":"e_1_3_6_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.08.022"},{"key":"e_1_3_6_108_1","first-page":"113","volume-title":"The vaccination: theory and practice","author":"Hirayama M","year":"1975","unstructured":"Hirayama M. Smallpox vaccination in Japan. In: Fukumi H, editor. The vaccination: theory and practice. Tokyo: International Medical Foundation of Japan; 1975. p. 113\u2013124."},{"key":"e_1_3_6_109_1","first-page":"87","volume-title":"Vaccinia Viruses as Vectors for Vaccine Antigens, Proceedings of the Workshop on Vaccinia Viruses as Vectors for Vaccine Antigens, November 13-14, 1985, Chevy Chase, Maryland, USA","author":"Hashizume SO","year":"1985","unstructured":"Hashizume SO, Yoshizawa H, Morita M, et al. Properties of attenuated mutant of vaccinia virus, LC16m8, derived from Lister strain. In: Quinnan G Jr., editor. Vaccinia Viruses as Vectors for Vaccine Antigens, Proceedings of the Workshop on Vaccinia Viruses as Vectors for Vaccine Antigens, November 13-14, 1985, Chevy Chase, Maryland, USA; (NY). Elsevier; 1985. p. 87\u201399."},{"key":"e_1_3_6_110_1","unstructured":"Yamaguchi M Kimura M Hirayama M. Vaccination Research Group Research Report. [translated from Japanese to English]. Clinic & Virus. 1975;3:269\u2013279."},{"key":"e_1_3_6_111_1","unstructured":"Hirayama M. Research summary of an attenuated LC16m8 smallpox vaccine by the Smallpox Vaccine Research Committee (SVRC). Manuscript dated 2005 December 15 from Japan MHLW. [English]."},{"key":"e_1_3_6_112_1","first-page":"229","article-title":"Basics of new attenuated vaccine strain LC16m8","volume":"3","author":"Hashizume S","year":"1975","unstructured":"Hashizume S. Basics of new attenuated vaccine strain LC16m8. [translated from Jpn to Engl] Clinic & Virus. 1975;3:229\u2013235.","journal-title":"[translated from Jpn to Engl] Clinic & Virus"},{"key":"e_1_3_6_113_1","unstructured":"Biologics KM. Prescribing information: Freeze-dried smallpox vaccine prepared in cell culture LC16 \u201cKMB.\u201d Revised Sep 2023 (version 1). Available from: www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/261976_631340KD1037_2_07 [Japanese]."},{"issue":"1","key":"e_1_3_6_114_1","first-page":"1","article-title":"Meeting of the Strategic Advisory Group of Experts on immunization, November 2013 -- conclusions and recommendations","volume":"89","year":"2014","unstructured":"Meeting of the Strategic Advisory Group of Experts on immunization, November 2013 -- conclusions and recommendations. Wkly Epidemiol Rec. 2014;89\u200e(1):1\u201319. Available from: www.who.int\/publications\/i\/item\/WER8901","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_3_6_115_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02642-05"},{"key":"e_1_3_6_116_1","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.JJID.2016.417"},{"key":"e_1_3_6_117_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0406671102"},{"key":"e_1_3_6_118_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.18.11873-11891.2005"},{"key":"e_1_3_6_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.03.029"},{"key":"e_1_3_6_120_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00199-14"},{"key":"e_1_3_6_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.076"},{"key":"e_1_3_6_122_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.289"},{"key":"e_1_3_6_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.09.067"},{"key":"e_1_3_6_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2023.07.005"},{"key":"e_1_3_6_125_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.034207-0"},{"key":"e_1_3_6_126_1","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.12.4.520-524.2005"},{"key":"e_1_3_6_127_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2242219"},{"key":"e_1_3_6_128_1","doi-asserted-by":"publisher","DOI":"10.1101\/2024.06.06.24308551"},{"key":"e_1_3_6_129_1","doi-asserted-by":"publisher","DOI":"10.3390\/v15122396"},{"key":"e_1_3_6_130_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.1058807"},{"key":"e_1_3_6_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.05.043"},{"key":"e_1_3_6_132_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid3005.230676"},{"key":"e_1_3_6_133_1","doi-asserted-by":"publisher","DOI":"10.1089\/bsp.2005.3.198"},{"key":"e_1_3_6_134_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-7625.2006.00378.x"},{"key":"e_1_3_6_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.01.017"},{"key":"e_1_3_6_136_1","unstructured":"Moderna NCT05995275. A Study to Investigate the Safety Tolerability And Immune Response of a Range of Doses of mRNA-1769 Compared with Placebo in Healthy Participants From \u226518 Years of Age to <50 Years of Age. [cited 2024 Jun 18]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05995275"},{"key":"e_1_3_6_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114269"}],"container-title":["Expert Review of Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14760584.2024.2397006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T09:48:08Z","timestamp":1759830488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14760584.2024.2397006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":137,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/14760584.2024.2397006"],"URL":"https:\/\/doi.org\/10.1080\/14760584.2024.2397006","relation":{},"ISSN":["1476-0584","1744-8395"],"issn-type":[{"value":"1476-0584","type":"print"},{"value":"1744-8395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierv20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-05-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}